Bromocriptine and Insulin Sensitivity (the BIS study)

Bromocriptine and Insulin Sensitivity (the BIS study) - BIS study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON42270

Enrollment

Registered

2014-07-15

Start date

2014-10-09

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin Sensitivity Sensitivity for insulin

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Male - Caucasian origin - Subjects should be able and willing to give informed consent - 18-35 years old - BMI range of 19-23 kg/m2 or BMI> 27 kg/2

Exclusion criteria

Exclusion criteria: - Renal failure (creatinine>135mmol/l) - Liver failure (AST/ALT > 3 times higher than the normal upper value) - Daily use of prescription medication and/or drugs - Known hypersensitivity to bromocriptine. - Uncontrolled hypertension - Known history of coronary artery disease or valvulopathy - History of severe psychiatric disorders. - Prolactin-releasing pituitary tumor (prolactinoma).

Design outcomes

Primary

Measure	Time frame
Difference in insulin sensitivity when bromocriptine is used in the morning or in the evening in lean and obese males.	—

Secondary

Measure	Time frame
- Difference in effect of bromocriptine treatment on insulin sensitivity between lean and obese males. - Difference in energy expenditure due to bromocriptine usage at different time points in lean and obese males.	—

Countries

Netherlands

Outcome results